$VVOS
Vivos Therapeutics, Inc.

2022 Q1 Form 10-Q Financial Statement

#000149315222013889 Filed on May 16, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $3.460M $3.450M
YoY Change 0.29%
Cost Of Revenue $1.093M $760.0K
YoY Change 43.82%
Gross Profit $2.367M $2.690M
YoY Change -12.01%
Gross Profit Margin 68.41% 77.97%
Selling, General & Admin $9.028M $5.920M
YoY Change 52.5%
% of Gross Profit 381.41% 220.07%
Research & Development $100.0K
YoY Change
% of Gross Profit 4.22%
Depreciation & Amortization $41.00K $180.0K
YoY Change -77.22%
% of Gross Profit 1.73% 6.69%
Operating Expenses $9.190M $6.090M
YoY Change 50.9%
Operating Profit -$6.823M -$3.400M
YoY Change 100.68%
Interest Expense $10.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net $21.00K
YoY Change
Pretax Income -$5.515M -$3.400M
YoY Change 62.21%
Income Tax
% Of Pretax Income
Net Earnings -$5.515M -$3.400M
YoY Change 62.21%
Net Earnings / Revenue -159.39% -98.55%
Basic Earnings Per Share -$0.25
Diluted Earnings Per Share -$259.7K -$186.7K
COMMON SHARES
Basic Shares Outstanding 21.23M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.83M $14.06M
YoY Change 26.8%
Cash & Equivalents $17.83M $14.06M
Short-Term Investments
Other Short-Term Assets $2.771M $930.0K
YoY Change 197.96%
Inventory
Prepaid Expenses
Receivables $1.002M $1.750M
Other Receivables $0.00 $0.00
Total Short-Term Assets $21.60M $16.74M
YoY Change 29.04%
LONG-TERM ASSETS
Property, Plant & Equipment $4.427M $1.060M
YoY Change 317.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $354.0K $370.0K
YoY Change -4.32%
Total Long-Term Assets $7.955M $5.210M
YoY Change 52.69%
TOTAL ASSETS
Total Short-Term Assets $21.60M $16.74M
Total Long-Term Assets $7.955M $5.210M
Total Assets $29.56M $21.95M
YoY Change 34.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $877.0K $870.0K
YoY Change 0.8%
Accrued Expenses $3.529M $2.460M
YoY Change 43.46%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $1.160M
YoY Change
Total Short-Term Liabilities $6.851M $7.300M
YoY Change -6.15%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $110.0K
YoY Change -100.0%
Other Long-Term Liabilities $1.850M $210.0K
YoY Change 780.95%
Total Long-Term Liabilities $1.850M $320.0K
YoY Change 478.13%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.851M $7.300M
Total Long-Term Liabilities $1.850M $320.0K
Total Liabilities $8.701M $7.610M
YoY Change 14.34%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $20.86M $14.34M
YoY Change
Total Liabilities & Shareholders Equity $29.56M $21.95M
YoY Change 34.65%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$5.515M -$3.400M
YoY Change 62.21%
Depreciation, Depletion And Amortization $41.00K $180.0K
YoY Change -77.22%
Cash From Operating Activities -$6.082M -$3.860M
YoY Change 57.56%
INVESTING ACTIVITIES
Capital Expenditures -$120.0K -$260.0K
YoY Change -53.85%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$120.0K -$260.0K
YoY Change -53.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -30.00K
YoY Change
NET CHANGE
Cash From Operating Activities -6.082M -3.860M
Cash From Investing Activities -120.0K -260.0K
Cash From Financing Activities -30.00K
Net Change In Cash $0.00 -4.150M
YoY Change -100.0%
FREE CASH FLOW
Cash From Operating Activities -$6.082M -$3.860M
Capital Expenditures -$120.0K -$260.0K
Free Cash Flow -$5.962M -$3.600M
YoY Change 65.61%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Other Liabilities
OtherLiabilities
USD
CY2021Q1 VVOS Ppp Loan Forgiveness
PppLoanForgiveness
USD
CY2022Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
USD
CY2022Q1 VVOS Accretion Of Discount On Convertible Debt
AccretionOfDiscountOnConvertibleDebt
USD
CY2021Q1 VVOS Forgiveness Of Indebtness Income
ForgivenessOfIndebtnessIncome
USD
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
USD
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2022Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
USD
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
CY2022Q1 VVOS Fair Value Of Warrants Issued In Asset Purchase
FairValueOfWarrantsIssuedInAssetPurchase
USD
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
USD
CY2021Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
USD
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.00
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P1Y1M6D
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.23
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2938000 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.86
CY2022Q1 VVOS Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm
P2Y10M24D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1950000 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.50
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y5M1D

Files In Submission

Name View Source Status
0001493152-22-013889-index-headers.html Edgar Link pending
0001493152-22-013889-index.html Edgar Link pending
0001493152-22-013889.txt Edgar Link pending
0001493152-22-013889-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
form10-q_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vvos-20220331.xsd Edgar Link pending
vvos-20220331_cal.xml Edgar Link unprocessable
vvos-20220331_def.xml Edgar Link unprocessable
vvos-20220331_lab.xml Edgar Link unprocessable
vvos-20220331_pre.xml Edgar Link unprocessable